Weiwei Tan

8.9k citations

59 papers · 1.9k indexed · 1 hit paper · h-index 20

Impact in

Oncology top 2%
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
Pulmonary and Respiratory Medicine top 2%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Brain Metastases and Treatment

Papers in

Oncology 35
- Colorectal Cancer Treatments and Studies 16
- HER2/EGFR in Cancer Research 9
- Lung Cancer Research Studies 7
- Pancreatic and Hepatic Oncology Research 6
Pulmonary and Respiratory Medicine 37
- Lung Cancer Treatments and Mutations 32
- Advanced Breast Cancer Therapies 5

Co-authors: Keith D. Wilner Zhongzhou Shen Daniel B. Costa Wee-Lee Yeo Susumu Kobayashi Shuchi S. Pandya Benjamin Solomon D. Ross Camidge
Journals: Journal of Clinical Oncology (5 papers)Clinical Cancer Research (3 papers)Journal of Thoracic Oncology (3 papers)Annals of Oncology (3 papers)Cancer Research (3 papers)
Partner nations: United States China Italy

In The Last Decade

Weiwei Tan

56 papers receiving 1.9k citations

Hit Papers

align trajectories log scale

CSF Concentration of the Anaplastic Lymphoma Kinase Inhibitor Crizotinib 2011 · 474 citations

Peers

Countries citing papers authored by Weiwei Tan

Since Specialization

Citations

This map shows the geographic impact of Weiwei Tan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Weiwei Tan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Weiwei Tan more than expected).

Fields of papers citing papers by Weiwei Tan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Weiwei Tan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Weiwei Tan. The network helps show where Weiwei Tan may publish in the future.

Co-authors

The 25 scholars most cited alongside Weiwei Tan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Weiwei Tan Line = papers co-authored together Weiwei Tan links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Effect of vepdegestrant, a PROTAC oestrogen receptor degrader, on dabigatran and rosuvastatin pharmacokinetics in healthy participants British Journal of Clinical Pharmacology ·Derek Z. Yang, Li Zhou, Jennifer A. Winton, Kyle Matschke, Constantino Kantaridis, Kenneth George Doyle, Kimberly C. Lee, Naihan Chen, Yuanyuan Zhang, Weiwei Tan	2025	1
2	DeformFlowNet: A deformable transformer with optical flow constraint for interventricular septum segmentation in echocardiography videos Biomedical Signal Processing and Control ·Qiang Guo, Xu Zhou, Weiwei Tan, Yiwen Shen, Shupeng Liu, Bo Zhang, Qi Zhang	2025	0
3	Abstract PS15-03: Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, plus palbociclib in ER–positive/human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer: phase 1b cohort Cancer Research ·Erika Hamilton, Rinath Jeselsohn, Sara A. Hurvitz, Dejan Juric, Hyo S. Han, Melinda L. Telli, George Zahrah, Rita Nanda, Yuanyuan Zhang, Weiwei Tan, Elizabeth K. Duperret, Eric Zhi, Cecile Mather, Anne F. Schott	2024	2
4	Effects of H2-Receptor Antagonists on the Exposure of Dacomitinib Pharmaceutics ·Jian Liu, Swan Lin, Anthony Huynh, Weiwei Tan	2024	0
5	218P Vepdegestrant, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, plus palbociclib (palbo) in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: Updated phase Ib cohort results ESMO Open ·E.P. Hamilton, S.A. Hurvitz, Nicholas P. McAndrew, Melinda L. Telli, Dejan Juric, Hyo S. Han, Rita Nanda, G. Zahrah, Yaowen Zhang, Weiwei Tan, Elizabeth K. Duperret, Eric Zhi, C. Mather, R. Jeselsohn	2024	7
6	Efficacy in patients with EGFR -positive non-small-cell lung cancer treated with dacomitinib who had skin adverse events: post hoc analyses from ARCHER 1050 Future Oncology ·Xingxiang Pu, Juan Li, Bo Zhang, Jinyao Zhang, Tony Mok, Kazuhiko Nakagawa, Rafael Rosell, Ying Cheng, Xiangdong Zhou, Maria Rita Miglorino, Seiji Niho, Ki Hyeong Lee, J. Corral, Adam Płużański, Junling Li, R. Linke, Fang Pan, Yiyun Tang, Weiwei Tan, Lin Wu	2024	2
7	264TiP TACTIVE-K: Phase Ib/II study of vepdegestrant, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, in combination with PF-07220060, a cyclin-dependent kinase (CDK)4 inhibitor, in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer ESMO Open ·Melinda L. Telli, CD Gawryletz, Wei Mo, Amita Patnaik, Dongrui R. Lu, Marco Mazzoletti, Olga Valota, Simrit Parmar, Weiwei Tan, Toru Mukohara	2024	3
8	390P Vepdegestrant, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: Update of dose escalation results from a phase I/II trial Annals of Oncology ·Erika Hamilton, Hyo S. Han, Anne F. Schott, Antoinette R. Tan, Rita Nanda, Dejan Juric, N. Hunter, Pamela N. Münster, Bruno Fang, G. Zahrah, J. Ranciato, Richard Gedrich, Eric Zhi, Y. Zhang, Weiwei Tan, C. Mather, Jessica M. Perkins, Sibyl Anderson, Sara A. Hurvitz	2023	12
9	On Gesell Evaluation System for Disabled Children in Minority Areas Journal of Healthcare Engineering ·Guozhi Chen, Weiwei Tan, Yu Shi, Ming Chen, Qin Huang, Yingying Lin, Jinsheng Jiang, Wen-Lung Chang, Yanzhi Huang	2022	1
10	Circular RNA circ-ERBB2 promotes HER2-positive breast cancer progression and metastasis via sponging miR-136-5p and miR-198 Journal of Translational Medicine ·Jin-xiu Zhong, Yunyuan Kong, Rong-guang Luo, Guo-jin Xia, Wenxing He, Xuezhong Chen, Weiwei Tan, Qingjie Chen, Yu-yin Huang, Yan-xing Guan	2021	17
11	Bioequivalence and pharmacokinetic comparison of two fixed dose combination of Metformin/Glibenclamide formulations in healthy subjects under fed condition PubMed ·Chee Tao Chang, Jazz Rui Xia Ang, Judy M.Y. Wong, Siew Siew Tan, Sabin Chin, A B Lim, Weiwei Tan, Kah Hay Yuen	2020	3
12	Evaluation of the potential effect of dacomitinib, an EGFR tyrosine kinase inhibitor, on ECG parameters in patients with advanced non-small cell lung cancer Investigational New Drugs ·Weiwei Tan, Nagdeep Giri, Susan Quinn, Keith D. Wilner, Kourosh Parivar	2019	5
13	Tumor-to-tumor metastasis: a rare case of breast carcinoma metastasizing to a pheochromocytoma, and a literature review Diagnostic Pathology ·Weiwei Tan, Lili Tao, Zhuping Zhou, Weihua Yin, Yao‐Li Chen	2019	7
14	Genome-wide identification and expression analysis of the 14-3-3 gene family in soybean ( Glycine max ) PeerJ ·Yongbin Wang, Lei Ling, Zhenfeng Jiang, Weiwei Tan, Zhaojun Liu, Licheng Wu, Yuanling Zhao, Shanyong Xia, Jun Ma, Guangjin Wang, Wenbin Li	2019	24
15	Combining YESS and TESSYS techniques during percutaneous transforaminal endoscopic discectomy for multilevel lumbar disc herniation Medicine ·Shenghua He, Zhitao Sun, Yeguang Wang, Dujun Ma, Weiwei Tan, Juyi Lai	2018	21
16	Clinical Implications of the Pharmacokinetics of Crizotinib in Populations of Patients with Non–Small Cell Lung Cancer Clinical Cancer Research ·Erjian Wang, Dana J. Nickens, Akintunde Bello, Reza Khosravan, Michael Amantea, Keith D. Wilner, Kourosh Parivar, Weiwei Tan	2016	20
17	ZNF32 contributes to the induction of multidrug resistance by regulating TGF-β receptor 2 signaling in lung adenocarcinoma Cell Death and Disease ·Jun Li, Jie Ao, Kai Li, Jie Zhang, Yanyan Li, Le Zhang, Yuyan Wei, Di Gong, Junping Gao, Weiwei Tan, Lugang Huang, Lunxu Liu, Ping Lin, Yuquan Wei	2016	16
18	Phase I Results from a Study of Crizotinib in Combination with Erlotinib in Patients with Advanced Nonsquamous Non–Small Cell Lung Cancer Journal of Thoracic Oncology ·Sai‐Hong Ignatius Ou, Ramaswamy Govindan, Keith D. Eaton, Gregory A. Otterson, Martin Gutierrez, Alain C. Mita, Athanassios Argiris, Nicoletta Brega, Tiziana Usari, Weiwei Tan, Steffan N. Ho, Francisco Robert	2016	40
19	Phase 1b study of crizotinib in combination with pembrolizumab in patients (pts) with untreated ALK-positive (+) advanced non-small cell lung cancer (NSCLC) Annals of Oncology ·F.R. Vizcarrondo, Sandip Pravin Patel, Nathan A. Pennell, Suchita Pakkala, Howard West, Robert A. Kratzke, Jamal Tarazi, Keith D. Wilner, Anna Polli, Weiwei Tan, Y. Liu, Olga Valota, Bilal Piperdi, Karen L. Reckamp	2016	2
20	Evaluation of crizotinib absolute bioavailability, the bioequivalence of three oral formulations, and the effect of food on crizotinib pharmacokinetics in healthy subjects The Journal of Clinical Pharmacology ·Huiping Xu, Melissa O’Gorman, Tanya Boutros, Nicoletta Brega, Constantino Kantaridis, Weiwei Tan, Akintunde Bello	2014	36

About Weiwei Tan

Weiwei Tan is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Toxicology, Cancer Research and Pharmacology, having authored 59 papers that have together received 1.9k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (32 papers), Colorectal Cancer Treatments and Studies (16 papers), HER2/EGFR in Cancer Research (9 papers), PI3K/AKT/mTOR signaling in cancer (7 papers), Lung Cancer Research Studies (7 papers), Pancreatic and Hepatic Oncology Research (6 papers), Protein Degradation and Inhibitors (5 papers) and Advanced Breast Cancer Therapies (5 papers). The work is most often cited by research in Oncology (1.0k citations), Pulmonary and Respiratory Medicine (1.2k citations), Cancer Research (232 citations), Hepatology (115 citations) and Molecular Biology (809 citations). Weiwei Tan has collaborated with scholars based in United States, China and Italy. Frequent co-authors include Keith D. Wilner, Zhongzhou Shen, Daniel B. Costa, Wee-Lee Yeo, Susumu Kobayashi, Shuchi S. Pandya, Benjamin Solomon, D. Ross Camidge, Sai‐Hong Ignatius Ou and Ravi Salgia. Their work appears in journals such as Journal of Clinical Oncology, Clinical Cancer Research, Journal of Thoracic Oncology, Annals of Oncology and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact